Skip to main
OPRX
OPRX logo

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp has demonstrated significant financial strength, with contracted revenue increasing by 30% year-over-year, suggesting a robust demand for its digital health messaging solutions. The company's revenue guidance for 2025 exceeds consensus expectations, projecting a growth of 13-17%, and indicates strong visibility with over 85% confidence in total revenue for that year. Additionally, the company's effective management of operating expenses, supported by a headcount capable of sustaining a $150 million revenue run-rate, bodes well for continued margin expansion moving forward.

Bears say

As of the latest reports, OptimizeRx has experienced declining revenue growth, which raises concerns about its ability to sustain its business model in a competitive healthcare market. The company's increasing operational costs, particularly in technology and personnel, have resulted in reduced profitability margins, further stressing its financial health. Additionally, the dependence on a limited number of clients for a significant portion of revenue poses a risk to long-term stability and growth potential.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.